Dupixent is one of the most searched medicine names on akpharma.in — consistently generating nearly 2,000 impressions per month and sitting at position 5 on Google for dupixent-related queries. The searches are coming from two very different groups of people: patients and families who have been prescribed Dupixent and want to understand what it is, and hospital pharmacists and procurement teams who need to source it reliably for their departments.
This article is written for both. It covers what Dupixent is, how it works, what it is approved for in India, what the supply chain looks like, and what patients and families need to know before starting treatment.
What Is Dupixent?
Dupixent is the brand name for Dupilumab — a fully human monoclonal antibody developed by Regeneron Pharmaceuticals and Sanofi. It is administered as a subcutaneous injection, supplied in pre-filled syringes and pre-filled pens, and is available in multiple dose strengths depending on the indication and patient age group.
Dupilumab works by blocking the interleukin-4 (IL-4) and interleukin-13 (IL-13) signalling pathways — two key cytokines involved in type 2 inflammatory responses. According to the approved prescribing information and published immunology literature, IL-4 and IL-13 drive the inflammatory cascade underlying atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic oesophagitis, and prurigo nodularis — all conditions in which Dupixent has regulatory approval. By blocking the shared receptor component (IL-4Rα) that both IL-4 and IL-13 signal through, Dupilumab effectively dampens the type 2 inflammatory response across all these conditions.
This is why Dupixent has become one of the most broadly approved biologics in modern medicine — the same biological pathway (type 2 inflammation) underlies multiple conditions, and a single medicine blocking that pathway has proven effective across all of them.
For the full clinical background on Dupilumab’s mechanism and approved indications, the FDA prescribing information for Dupilumab and the European Medicines Agency (EMA) Dupixent product page provide comprehensive reference material.
What Is Dupixent Approved For?
According to the approved prescribing information, Dupixent is indicated for:
Atopic Dermatitis (Eczema):
Adults, adolescents, and children with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical therapies or for whom topical therapies are not appropriate. This is the original and most widely prescribed indication for Dupixent, and the one most commonly behind the searches reaching akpharma.in. Dupixent can be used as monotherapy or in combination with topical corticosteroids in this setting.
Asthma:
Adults and adolescents aged 12 years and older with moderate-to-severe asthma characterised by an eosinophilic phenotype or oral corticosteroid-dependent asthma. Dupixent is used as an add-on maintenance treatment — it is not a rescue inhaler and is not appropriate for acute asthma attacks.
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP):
Adults with inadequately controlled chronic rhinosinusitis with nasal polyps, as an add-on maintenance treatment. Dupixent reduces nasal polyp burden and improves nasal obstruction, loss of smell, and overall disease control in this condition.
Eosinophilic Oesophagitis (EoE):
Adults and adolescents aged 12 years and older with eosinophilic oesophagitis — an allergic inflammatory condition of the oesophagus that causes swallowing difficulty, food impaction, and chest pain.
Prurigo Nodularis:
Adults with prurigo nodularis — a chronic skin condition characterised by intensely itchy nodules on the skin driven by type 2 inflammation.
Alopecia Areata:
Adults with severe alopecia areata — an autoimmune condition causing hair loss — in markets where this indication has received regulatory approval.
For detailed indication information by age group and dose, refer to MedlinePlus Dupilumab and the National Eczema Association.
The Clinical Evidence — Key Trials
SOLO 1 and SOLO 2 (Atopic Dermatitis)
Published in the New England Journal of Medicine (2016), the pivotal SOLO 1 and SOLO 2 trials evaluated Dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical therapies. Key findings demonstrated that 36-38% of patients achieved clear or almost clear skin (IGA 0-1) at 16 weeks with Dupilumab, compared to approximately 8-10% with placebo — a dramatic improvement over the placebo response rate that established Dupixent as a step-change in atopic dermatitis treatment for patients who had failed topical therapy.
QUEST Trial (Asthma)
Published in The Lancet (2018), the QUEST trial evaluated Dupilumab as add-on maintenance therapy in patients with uncontrolled, moderate-to-severe asthma. Key findings demonstrated a significant reduction in severe asthma exacerbation rate and significant improvement in lung function (FEV1) in patients with elevated baseline eosinophil counts — supporting the eosinophilic phenotype as the primary predictor of Dupilumab response in asthma.
SINUS-24 and SINUS-52 Trials (Chronic Rhinosinusitis With Nasal Polyps)
These trials evaluated Dupilumab in patients with inadequately controlled chronic rhinosinusitis with nasal polyps, demonstrating significant reductions in nasal polyp score, nasal congestion, and loss of smell — with a meaningful proportion of patients avoiding surgical intervention as a result of treatment.
For the full clinical evidence base across all indications, the American Academy of Allergy, Asthma and Immunology (AAAAI) and British Association of Dermatologists (BAD) publish clinical guidance and evidence summaries.
Available Strengths and Dosing Reference
Dupixent is supplied as a pre-filled syringe or pre-filled pen:
| Presentation | Strength | Approved For |
|---|---|---|
| Pre-filled syringe / pen | 300mg/2mL | Adults — atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis |
| Pre-filled syringe | 200mg/1.14mL | Paediatric and adolescent dosing — atopic dermatitis, asthma |
| Pre-filled syringe | 100mg/0.67mL | Paediatric dosing — atopic dermatitis in younger children |
General dosing schedule (per approved prescribing information — dosing by the treating physician):
| Indication | Adult Loading Dose | Maintenance |
|---|---|---|
| Atopic Dermatitis (adults) | 600mg (two 300mg injections) | 300mg every 2 weeks or every 4 weeks depending on severity |
| Asthma | 400mg or 600mg (indication-specific) | 200mg or 300mg every 2 weeks |
| CRSwNP | 300mg | 300mg every 2 weeks |
All dosing, including dose intervals and any adjustments for specific patient populations, is determined by the prescribing specialist in accordance with the approved label. Dupixent is administered subcutaneously — either by a healthcare professional or, following appropriate training, by the patient or caregiver at home.
What Patients and Families Need to Know Before Starting Dupixent
For patients in India who have been prescribed Dupixent, several practical questions tend to arise immediately. This section addresses the most common ones.
Is Dupixent a steroid?
No. Dupixent is a biologic monoclonal antibody — an entirely different class of medicine from topical or oral steroids. It does not carry the side effects associated with long-term steroid use (skin thinning, adrenal suppression, bone loss). It works by blocking specific inflammatory signalling pathways rather than broadly suppressing the immune system.
How is Dupixent given — and can patients self-inject?
Dupixent is given as a subcutaneous injection — under the skin, typically in the thigh, abdomen, or upper arm. Many patients and caregivers learn to self-inject at home after initial training from their physician or nurse. The pre-filled pen format is specifically designed for ease of self-administration. For patients who prefer clinic-administered injections, this can be arranged with the treating specialist.
How long before Dupixent works?
In atopic dermatitis, many patients begin to notice improvement in itch within the first two weeks of treatment, with significant skin improvement typically visible by weeks 4 to 16. In asthma, improvements in lung function and reductions in exacerbation rate are typically seen within the first few months. For nasal polyps, meaningful symptom improvement typically occurs over the first 4 to 24 weeks of treatment. The full treatment response may not be apparent until 16 to 24 weeks of consistent use.
Does Dupixent need to be stored in a fridge?
Yes — Dupixent must be refrigerated between 2°C and 8°C. It should not be frozen. Before injection, the pre-filled syringe or pen can be removed from the refrigerator and allowed to reach room temperature (approximately 45 minutes) to reduce injection site discomfort. This cold chain requirement means that sourcing Dupixent through a licensed specialty pharmaceutical distributor with cold chain infrastructure — rather than through informal channels — is essential for product integrity.
Is there a Patient Assistance Program for Dupixent?
Sanofi and Regeneron have historically operated patient assistance programs for Dupixent in various markets. For patients in India who cannot afford Dupixent at market price, A.K. Pharma can advise on current Patient Assistance Program availability and eligibility. Contact us at 011 4172 6999 or WhatsApp +91 9810034827 for current information.
Side Effects — What to Expect
Dupixent has a generally favourable safety profile compared to systemic immunosuppressants previously used in severe atopic dermatitis. The most commonly reported side effects in clinical trials include:
Injection site reactions: Pain, redness, and swelling at the injection site — the most commonly reported side effect, typically mild and improving over time with continued treatment.
Conjunctivitis and eye irritation: Reported in a proportion of atopic dermatitis patients — particularly relevant for the atopic dermatitis indication where eye involvement is part of the disease spectrum. Patients experiencing conjunctivitis during Dupixent treatment should discuss this with their dermatologist or ophthalmologist.
Facial and neck redness (facial erythema): Reported in some atopic dermatitis patients — typically mild and managed with moisturisers and topical therapies as directed by the treating dermatologist.
Cold sores (herpes simplex): Patients with a history of herpes simplex infections may experience reactivation during Dupixent treatment — antiviral prophylaxis may be considered in at-risk patients per the treating physician’s assessment.
Eosinophilia: Transient increases in blood eosinophil counts have been reported — typically not clinically significant but monitored in patients receiving Dupixent for asthma.
Full side effect information is available at FDA Dupilumab Safety Information and Drugs.com Dupilumab.
What Hospital Pharmacists Need to Know for Procurement
For hospital pharmacy teams managing Dupixent procurement, the key practical considerations are:
Cold chain throughout. Every Dupixent delivery must have maintained 2°C to 8°C from the distributor’s cold storage through to hospital pharmacy receipt. A.K. Pharma provides temperature monitoring documentation with every cold chain delivery — this should be checked and retained as part of the pharmacy’s acceptance procedure.
Multiple strengths in practice. Hospitals managing both adult and paediatric patients on Dupixent may need to stock multiple pre-filled syringe strengths — 300mg, 200mg, and 100mg. Confirm the specific strength and quantity required against the treating specialist’s prescriptions before ordering.
Ongoing treatment — plan supply consistently. Dupixent is a long-term, continuous therapy for most patients. A gap in supply — even a short one — can affect disease control, particularly in patients with severe atopic dermatitis or poorly controlled asthma. Planning supply on a rolling basis rather than ordering reactively is strongly advisable.
Originator product only. Unlike many medicines on A.K. Pharma’s range where both originator and Indian generic options exist, Dupixent (Dupilumab) is currently only available as the originator product from Regeneron/Sanofi. Any product claiming to be a Dupilumab biosimilar for the Indian market should be verified carefully with the treating specialist before substitution.
Where to Source Genuine Dupixent in India
A.K. Pharma is a licensed medicine distributor in Delhi and pharmaceutical distributor in Delhi supplying genuine Dupixent (Dupilumab) to hospitals, dermatology centres, pulmonology departments, and pharmacies across India — with cold chain-compliant delivery and complete batch documentation for every shipment sourced from authorised Sanofi/Regeneron channels.
Related medicines for atopic dermatitis, asthma, and immune-mediated conditions available through A.K. Pharma:
- Dupixent (Dupilumab) — IL-4/IL-13 inhibitor for atopic dermatitis, asthma, CRSwNP and more
- Xolair (Omalizumab) — anti-IgE biologic for severe allergic asthma and chronic urticaria
- Cibinqo (Abrocitinib) — oral JAK1 inhibitor for moderate-to-severe atopic dermatitis
- Nucala (Mepolizumab) — anti-IL-5 biologic for severe eosinophilic asthma
- Fasenra (Benralizumab) — anti-IL-5Rα biologic for severe eosinophilic asthma
- Histoglob — Histamine Dihydrochloride + Gamma Globulin for allergic conditions
- Browse all Immunosuppressant Medicines at A.K. Pharma
- Browse the full Products range at A.K. Pharma
- Learn about the Patient Assistance Program for eligible patients
- Learn about the Named Patient Program for special access pathways
Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for availability, pricing, and cold chain delivery scheduling.
Frequently Asked Questions
Q. What is Dupixent used for in India?
Dupixent (Dupilumab) is used for moderate-to-severe atopic dermatitis, moderate-to-severe asthma with eosinophilic phenotype or oral corticosteroid dependence, chronic rhinosinusitis with nasal polyps, eosinophilic oesophagitis, and prurigo nodularis — in the age groups and settings specified in the approved prescribing information.
Q. Is Dupixent a steroid?
No. Dupixent is a biologic monoclonal antibody that works by blocking IL-4 and IL-13 signalling pathways involved in type 2 inflammation. It is not a steroid and does not carry steroid-associated side effects.
Q. How is Dupixent administered and can patients self-inject?
Dupixent is administered as a subcutaneous injection. Many patients learn to self-inject at home using the pre-filled pen format after initial training from their physician or nurse. The treating specialist will advise on whether self-injection is appropriate for each patient.
Q. How long does Dupixent take to work for atopic dermatitis?
Many patients notice improvement in itch within the first two weeks, with significant skin clearing typically visible by weeks 4 to 16. Full treatment response may take up to 24 weeks of consistent treatment. The treating dermatologist will assess response at planned review appointments.
Q. Does Dupixent need to be kept in a fridge?
Yes — Dupixent must be stored between 2°C and 8°C and must not be frozen. Before injection, the pre-filled syringe or pen can be allowed to reach room temperature over approximately 45 minutes. Cold chain compliance throughout the supply chain — from distributor to hospital pharmacy to patient — is essential for product integrity.
Q. Is there a biosimilar version of Dupixent available in India?
As of mid-2026, Dupixent (Dupilumab) is only available as the originator product from Regeneron/Sanofi in India. Any product claiming to be a Dupilumab biosimilar for the Indian market should be verified carefully with the treating specialist before use.
Q. Is a Patient Assistance Program available for Dupixent in India?
Sanofi has historically operated patient support programs for Dupixent in various markets. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current information on any available patient assistance pathways for Dupixent in India.
Q. Is Dupixent available in India?
Yes — Dupixent is available through licensed specialty pharmaceutical distributors in India. A.K. Pharma supplies genuine Dupixent to hospitals, dermatology centres, and pulmonology departments across India with cold chain-compliant delivery. Contact us at 011 4172 6999 or WhatsApp +91 9810034827 for pricing and availability.
Q. What is the price of Dupixent in India?
Dupixent price in India varies by strength, quantity, and applicable patient support programs. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing.
Q. How does Dupixent compare to Cibinqo (Abrocitinib) for atopic dermatitis?
Both are approved for moderate-to-severe atopic dermatitis but work through different mechanisms — Dupixent is an injectable biologic blocking IL-4/IL-13, while Cibinqo is an oral JAK1 inhibitor. The treating dermatologist will advise on which is appropriate based on individual patient factors, disease severity, prior treatment history, and patient preference for injectable vs oral therapy.
Disclaimer: This article is intended for general informational and sourcing purposes only and does not constitute medical or clinical advice. All treatment decisions for atopic dermatitis, asthma, or any other Dupixent indication should be made by a qualified specialist in accordance with the approved prescribing information. A.K. Pharma is a licensed medicine distributor and does not provide clinical guidance.